Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: April 29, 2026
Event: Entry into a Material Definitive Agreement (Item 1.01) and Regulation FD Disclosure (Item 7.01).
On April 29, 2026, Inmune Bio Inc. entered into an Amended and Restated Material Transfer and License Agreement with its wholly-owned subsidiary, INmune Bio International (IMB), and Anthony Nolan (AN). This agreement amends and restates a prior collaboration originally signed in 2017 and amended in 2023. The Company has agreed to be bound by the terms and is jointly and severally liable for royalty obligations.
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. This 8-K focuses on contractual terms rather than financial performance results.
Contractual Financial Terms:
- Royalty Rate: 2% on net sales of each Product.
- Royalty Cap: Annual cap of £5,000,000.
- Service Fees: £400 plus VAT per umbilical cord tissue for Cell and Gene Therapies Services.
- Fee Adjustment: Starting January 1, 2027, fees may increase annually by no more than the percentage increase in the UK Consumer Price Index (CPI).
Material Changes Versus Prior Period
The primary material change is the formalization of the Company as a direct party to the agreement, whereas previously only the subsidiary (IMB) was a party. The Company has assumed joint and several liability for payment obligations. The agreement secures the long-term provision of high-quality umbilical cord tissue for the Company's CORDStrom™ platform and includes enhanced provisions for traceability and quality management under Good Manufacturing Practice (GMP) and Human Tissue Authority (HTA) standards.
Guidance, Outlook, and Risks
Outlook: The agreement is designed to secure long-term supply of donor materials to power the CORDStrom™ platform. The term continues until terminated or until ten years from the date of First Commercial Sale.
Termination Rights:
- Event of Default: Immediate termination by either party.
- Company/IMB: May terminate with 30 days' written notice.
- Anthony Nolan: May terminate with 6 months' written notice.
Risks/Contingencies: The license is exclusive but revocable until AN Donor Materials are "Used." The Company is exposed to ongoing royalty payments capped at £5 million annually and variable service fees tied to CPI.
Investor Verification Checklist
- Verify the definition of "First Commercial Sale" to determine the potential 10-year term duration.
- Review the full text of Exhibit 10.1 for specific definitions of "Net Sales" and "Product" to understand royalty calculation bases.
- Assess the impact of the £5,000,000 annual royalty cap on future gross margin projections.
- Confirm the status of the "Used" definition regarding the irrevocability of the license.
- Monitor the press release (Exhibit 99.1) for any additional strategic commentary not included in the 8-K summary.